Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-β-D-arabinofuranosylcytosine and bleomycin

Experimental Cell Research

Volumn 296, Issue 2, 2004, Pages 327-336

  Poot, Martin ^a   Jin, Xiaoyang ^a   Hill, Juliane P ^a   Gollahon, Katherine A ^a   Rabinovitch, Peter S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aging; Apoptosis; S phase; Sarcomas; TP53; WRN helicase exonuclease

Indexed keywords

BLEOMYCIN; CYTARABINE;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; EXPOSURE; GENE; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN P53 GENE; WERNER SYNDROME GENE;

EID: 2442438604     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.02.011     Document Type: Article

References (58)

1. Epstein C.J., Martin G.M., Schultz A.L., Motulsky A.G. Werner syndrome: a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine. 45:1966;177-221
2. Takeuchi F., Hanaoka F., Goto M., Yamada M.-A., Miyamoto T. Prolongation of S phase and whole cell cycle in Werner's syndrome fibroblasts. Exp. Gerontol. 17:1982;473-480
3. Poot M., Hoehn H., Rünger T.M., Martin G.M. Impaired S-phase transit of Werner syndrome cells expressed in lymphoblastoid cell lines. Exp. Cell Res. 202:1992;267-273
4. Hoehn H., Bryant E.M., Au K., Norwood T.H., Boman H., Martin G.M. Variegated translocation mosaicism in human skin fibroblast cultures. Cytogenet. Cell Genet. 15:1975;282-298
5. Fukuchi K., Martin G.M., Monnat R.J. Jr. Mutator phenotype of Werner syndrome is characterized by extensive deletions. Proc. Natl. Acad. Sci. U. S. A. 86:1989;5893-5897
6. Martin G.M., Sprague C.A., Epstein C.J. Replicative life-span of cultivated human cells. Effects of donor's age, tissue, and genotype. Lab. Invest. 23:1970;86-92
7. Rünger T.M., Bauer C., Dekant B., Möller K., Sobotta P., Czerny C., Poot M., Martin G.M. Hypermutable ligation of plasmid DNA ends in cells from patients with Werner syndrome. J. Invest. Dermatol. 102:1994;45-48
8. Prince P.R., Emond M.J., Monnat R.J. Jr. Loss of Werner syndrome protein function promotes aberrant mitotic recombination. Genes Dev. 15:2001;933-938
9. Yu C.E., Oshima J., Fu Y.H., Wijsman E.M., Hisama F., Alisch R., Matthews S., Nakura J., Miki T., Ouais S., Martin G.M., Mulligan J., Schellenberg G.D. Positional cloning of the Werner's syndrome gene. Science. 272:1996;258-262
10. Matsumoto T., Shimamoto A., Goto M., Furuichi Y. Impaired nuclear localization of defective DNA helicases in Werner's syndrome. Nat. Genet. 16:1997;335-356
11. Gray M.D., Shen J.C., Kamath-Loeb A.S., Blank A., Sopher B.L., Martin G.M., Oshima J., Loeb L.A. The Werner syndrome protein is a DNA helicase. Nat. Genet. 17:1997;100-103
12. Kamath-Loeb A.S., Shen J.-C., Loeb L.A., Fry M. Werner syndrome protein. II. Characterization of the integral 3′→5′ DNA exonuclease. J. Biol. Chem. 273:1998;34145-34150
13. Shen J.C., Gray M.D., Oshima J., Loeb L.A. Characterization of Werner syndrome protein DNA helicase activity: directionality, substrate dependence and stimulation by replication protein A. Nucleic Acids Res. 26:1998;2879-2885
14. Brosh R.M. Jr., Karow J.K., White E.J., Shaw N.D., Hickson I.D., Bohr V.A. Potent inhibition of Werner and Bloom helicases by DNA minor groove binding drugs. Nucleic Acids Res. 28:2000;2420-2430
15. Shen J.-C., Loeb L.A. Werner syndrome exonuclease catalyzes structure-dependent degradation of DNA. Nucleic Acids Res. 28:2000;3260-3268
16. von Kobbe C., Thoma N.H., Czyzewski B.K., Pavletich N.P., Bohr V.A. Werner syndrome protein contains three structure-specific DNA binding domains. J. Biol. Chem. 278:2003;52997-53006
17. Gebhardt E., Bauer R., Raub U., Schinzel M., Reuprecht K.W., Jonas J.B. Spontaneous and induced chromosomal instability in Werner syndrome. Hum. Genet. 80:1988;135-139
18. Ogburn C.E., Oshima J., Poot M., Chen R., Hunt K.E., Gollahon K.A., Rabinovitch P.S., Martin G.M. An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild type and homozygous mutants. Hum. Genet. 101:1997;121-125
19. Okada M., Goto M., Furuichi Y., Sugimoto M. Differential effects of cytotoxic drugs on mortal and immortalized B-lymphoblastoid cell lines from normal and Werner's syndrome patients. Biol. Pharm. Bull. 21:1998;235-239
20. Poot M., Gollahon K.A., Rabinovitch P.S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum. Genet. 104:1999;10-14
21. Poot M., Yom J.S., Whang S.H., Kato J.T., Gollahon K.A., Rabinovitch P.S. Werner syndrome cells are sensitive to DNA cross-linking drugs. FASEB J. 15:2001;1224-1226
22. Poot M., Gollahon K.A., Emond M.J., Silber J.R., Rabinovitch P.S. Werner syndrome diploid fibroblasts are sensitive to 4-nitroquinoline-N-oxide and 8-methoxypsoralen: implications for the disease phenotype. FASEB J. 16:2002;757-758
23. Poot M., Schuster A., Hoehn H. Cytostatic synergism between bromodeoxyuridine, bleomycin, cisplatin and chlorambucil demonstrated by a sensitive cell kinetic assay. Biochem. Pharmacol. 41:1991;1903-1909
24. Shevelev I.V., Hubscher U. The 3′ 5′ exonucleases. Nat. Rev., Mol. Cell. Biol. 3:2002;364-376
25. Skalski V., Lin Z.Y., Choi B.Y., Brown K.R. Substrate specificity of the p53-associated 3′-5′ exonuclease. Oncogene. 19:2000;3321-3329
26. Janus F., Albrechtsen N., Knippschild U., Wiesmuller L., Grosse F., Deppert W. Different regulation of the p53 core domain activities 3′-to-5′ exonuclease and sequence-specific DNA binding. Mol. Cell. Biol. 19:1999;2155-2168
27. Blander G., Kipnis J., Leal J.F., Yu C.E., Schellenberg G.D., Oren M. Physical and functional interaction between p53 and the Werner's syndrome protein. J. Biol. Chem. 274:1999;29463-29469
28. Brosh R.M. Jr., Karmakar P., Sommers J.A., Yang Q., Wang X.W., Spillare E.A., Harris C.C., Bohr V.A. p53 modulates the exonuclease activity of Werner syndrome protein. J. Biol. Chem. 276:2001;35093-35102
29. Wolf D., Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. U. S. A. 82:1985;790-794
30. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:1993;3186-3192
31. Bertrand P., Rouillard D., Boulet A., Levalois C., Soussi T., Lopez B.S. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene. 14:1997;1117-1122
32. Li F.P., Fraumeni J.F. Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann. Intern. Med. 71:1969;747-752
33. Varley J.M., Evans D.G.R., Birch J.M. Li-Fraumeni syndrome: a molecular and clinical review. Br. J. Cancer. 76:1997;1-14
34. Lombard D.B., Beard C., Johnson B., Marciniak R.A., Dausman J., Bronson R., Buhlman J.E., Lipman R., Curry R., Sharpe A., Jaenish R., Guarente L. Mutations in WRN gene in mice accelerate mortality in a p53-null background. Mol. Cell. Biol. 20:2000;3286-3291
35. Lebel M., Cardiff R.D., Leder P. Tumorigenic effect of nonfunctional p53 and p21 in mice mutant in the Werner syndrome helicase. Cancer Res. 61:2001;1816-1819
36. Povirk L.F., Han Y.H., Steighner R.J. Structure of bleomycin-induced DNA double-strand breaks: predominance of blunt ends and single-base 5′ extensions. Biochemistry. 28:1989;5808-5814
37. Malcomson R.D., Oren M., Wyllie A.H., Harrison D.J. p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br. J. Cancer. 72:1995;952-957
38. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263
39. Moser M.J., Kamath-Loeb A.S., Jacob J.E., Bennett S.E., Oshima J., Monnat R.J. Jr. WRN helicase expression in Werner syndrome cell lines. Nucleic Acids Res. 28:2000;648-654
40. Little J.B., Nagasawa H., Keng P.C., Yu Y., Li C.-Y. Absence of radiation-induced G1 arrest in two closely related human lymphoblastoid cell lines that differ in p53 status. J. Biol. Chem. 270:1995;11033-11036
41. Poot M., Gibson L.L., Singer V.L. Detection of apoptosis in live cells by MitoTracker Red CMXRos and SYTO dye flow cytometry. Cytometry. 27:1997;358-364
42. Rabinovitch P.S., Kubbies M., Chen Y.C., Schindler D., Hoehn H. BrdU-Hoechst flow cytometry: a unique tool for quantitative cell cycle analysis. Exp. Cell Res. 174:1988;309-318
43. Poot M., Silber J.R., Rabinovitch P.S. A novel flow cytometric technique for drug cytotoxicity gives results comparable to colony-forming assays. Cytometry. 48:2002;1-5
44. Fox M.H. A model for the computer analysis of synchronous DNA distributions by flow cytometry. Cytometry. 1:1980;71-77
45. Matsui Y., Tsuchida Y., Keng P.C. Effects of p53 mutations on cellular sensitivity to ionizing radiation. Am. J. Clin. Oncol. 24:2001;486-490
46. van Duin M., Vredeveldt G., Mayne L.V., Odijk H., Vermeulen W., Klein B., Weeda G., Hoeijmakers J.H., Westerveld A. The cloned human DNA excision repair gene ERCC-1 fails to correct xeroderma pigmentosum complementation groups A through I. Mutat. Res. 217:1989;83-92
47. Grosovsky A.J., Little J.B. Mutagenesis and lethality following S phase irradiation of xeroderma pigmentosum and normal human diploid fibroblasts with ultraviolet light. Carcinogenesis. 4:1983;1389-1393
48. Digweed M., Demuth I., Rothe S., Scholz R., Jordan A., Grotzinger C., Schindler D., Grompe M., Sperling K. SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Oncogene. 21:2002;4873-4878
49. Sengupta S., Linke S.P., Pedeux R., Yang Q., Farnsworth J., Garfield S.H., Valerie K., Shay J.W., Ellis N.A., Wasylyk B., Harris C.C. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J. 22:2003;1210-1222
50. Yang Q., Zhang R., Wang X.W., Spillare E.A., Linke S.P., Subramanian D., Griffith J.D., Li J.L., Hickson I.D., Shen J.C., Loeb L.A., Mazur S.J., Appella E., Brosh R.M. Jr., Karmakar P., Bohr V.A., Harris C.C. The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J. Biol. Chem. 277:2002;31980-31987
51. Saintigny Y., Makienko K., Swanson C., Emond M.J., Monnat R.J. Jr. Homologous recombination resolution defect in Werner syndrome. Mol. Cell. Biol. 22:2002;6971-6978
52. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27:2001;247-254
53. Kim S.T., Lim D.S., Canman C.E., Kastan M.B. Substrate specificities and identification of putative substrates of ATM kinase family members. J. Biol. Chem. 274:1999;37538-37543
54. Pichierri P., Rosselli F., Franchitto A. Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle. Oncogene. 22:2003;1491-1500
55. Kohli M., Jorgensen T.J. Lack of dependence on p53 for DNA double strand break repair of episomal vectors in human lymphoblasts. Biochem. Biophys. Res. Commun. 264:1999;702-708
56. Orren D.K., Brosh R.M. Jr., Nehlin J.O., Machwe A., Gray M.D., Bohr V.A. Enzymatic and DNA binding properties of purified WRN protein: high affinity binding to single-stranded DNA but not to DNA damage induced by 4NQO. Nucleic Acids Res. 27:1999;3557-3566
57. Laine J.P., Opresko P.L., Indig F.E., Harrigan J.A., von Kobbe C., Bohr V.A. Werner protein stimulates topoisomerase I DNA relaxation activity. Cancer Res. 63:2003;7136-7146
58. von Kobbe C., Harrigan J.A., May A., Opresko P.L., Dawut L., Cheng W.H., Bohr V.A. Central role for the Werner syndrome protein/poly(ADP-ribose) polymerase 1 complex in the poly(ADP-ribosyl)ation pathway after DNA damage. Mol. Cell. Biol. 23:2003;8601-8613